Italia markets closed

Bristol-Myers Squibb Company (BMY)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
75,57+1,11 (+1,49%)
Alla chiusura: 04:00PM EDT
75,68 +0,11 (+0,15%)
Dopo ore: 07:12PM EDT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set

    NEW ORLEANS, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion

  • GlobeNewswire

    FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, CTXS, HEPS and STNE

    CEDARHURST, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion Deadline: December 6, 2021MISLEADING PROSPECTUS To learn

  • GlobeNewswire

    SHAREHOLDER ALERT: CLAIMSFILER REMINDS BMY, OWLT, PTON, ZG INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company (BMY)Class: Investors who received Contingent Value Rights (“CVRs”) (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019Lead Plaintiff Motion Deadline: December 6, 2021MISLEADING PROSPECTUS To le